← Back to Home

Delayed Progression Still Falls Short of the Survival Threshold: FDA Does Not Approve Ivonescimab Lung Cancer Regimen

After EGFR-targeted therapy fails, ivonescimab plus chemotherapy can delay cancer progression, but the primary analysis did not establish an improvement in overall survival. This gap in evidence became the key obstacle to the U.S. marketing application.

By SURL BioNews

For lung cancer patients whose disease progresses again after targeted therapy, delaying cancer progression and extending life are both important treatment goals, but they represent two different types of evidence. Summit Therapeutics announced on November 15 that the U.S. Food and Drug Administration (FDA) had issued a complete response letter for the marketing application for ivonescimab plus chemotherapy. According to the company’s account, the trial’s failure to demonstrate a statistically significant improvement in overall survival was the central reason approval was not granted.

The application covered locally advanced or metastatic non-small cell lung cancer with EGFR mutations that had progressed after treatment with an EGFR tyrosine kinase inhibitor. Developed by Akeso and advanced with Summit’s involvement, ivonescimab is a bispecific antibody targeting both PD-1 and VEGF, seeking to combine the reversal of immune suppression with interference in tumor blood vessel formation.

The global phase 3 HARMONi trial supporting the application enrolled 438 patients previously treated with third-generation EGFR-targeted drugs. It used a randomized, double-blind design to compare ivonescimab plus platinum-based chemotherapy with placebo plus the same chemotherapy. According to a summary by *Targeted Oncology*, median progression-free survival was 6.8 months and 4.4 months in the two groups, respectively, with a hazard ratio for disease progression or death of 0.52, a statistically significant difference.

However, the other primary endpoint—overall survival—did not yield an equally clear result. In the primary analysis, median overall survival was 16.8 months and 14.0 months in the two groups, with a hazard ratio for death of 0.79 and a P value of 0.057, which did not reach statistical significance. This means the data showed a favorable trend but were insufficient to confirm a survival benefit under the prespecified analysis. The difference between the two medians also cannot be directly interpreted as the additional time every patient would live.

Longer follow-up brought another set of signals. In a subsequent post hoc analysis, the overall hazard ratio for death fell to 0.76, with a nominal P value of 0.0151. However, a post hoc analysis carries a different evidentiary weight from a prespecified primary analysis and cannot directly replace the original result that failed to meet the threshold. According to the contents of the response letter released by Summit, the FDA considered the progression-free survival advantage insufficient to support the favorable benefit-risk assessment required for approval in the absence of a statistically significant improvement in survival.

The treatment burden must also be weighed. *Targeted Oncology* reported that, in the primary analysis, rates of grade 3 or higher adverse events were 50.0% in the ivonescimab group and 42.2% in the control group, while serious adverse events occurred in 28.0% and 15.1%, respectively. Summit said the proportions discontinuing ivonescimab or placebo because of treatment-related adverse events were 7.3% and 5.0%, respectively, and stated that no new safety signals had emerged. However, the absence of new signals does not mean the two groups faced the same risks.

This complete response letter means the application cannot be approved in its current form. Bloomberg reported that Summit had previously estimated that more than 14,000 patients in the United States each year could meet the proposed indication, although this is the company’s estimate. Summit said it would continue clinical development in other cancer types and treatment settings. Those studies must each produce their own evidence, while the question left by this decision is whether the benefit of delaying disease progression, together with survival and safety data, can form an overall case sufficient to support marketing approval.

References

  1. Summit Therapeutics
  2. STAT
  3. Targeted Oncology
  4. Bloomberg via The Spokesman-Review